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The prognostic value of C-reactive protein, compared with ECOG performance status (ECOG-ps), in patients receiving alpha-
interferon treatment for advanced renal cancer was assessed in 58 patients. In all, 55 patients died on follow-up. On multivariate
analysis with ECOG-ps and C-reactive protein entered as covariates, only C-reactive protein was a significant independent predictor
of survival (HR 2.03, 95% CI 1.09–3.80, P¼0.026).
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Renal cell cancer continues to be one of the most lethal urological
tumours. Although only 2% of the population develop renal
cancer, one-third of these patients will have metastatic disease at
presentation and a further 40% will develop metastases during the
course of their disease, with an expected survival in the order of
8–10 months (Montie, 1994; World Health Organisation, 2000).
For the majority of these patients, immunotherapy remains the
treatment of choice; in the UK, alpha-interferon has become the
mainstay of treatment. The largest randomised trial comparing
alpha interferon with the existing hormonal drug medroxyproges-
terone acetate demonstrated a statistically significant survival
advantage for the interferon group (MRC RCC, 1999).
There is increasing evidence that the presence of a systemic
inflammatory response, as evidenced by an elevated circulating C-
reactive protein concentration, is an independent prognostic factor
in a number of hormone-independent cancers (Mahmoud and
Rivera, 2002; Forrest et al, 2003; McMillan et al, 2003). Two studies
have shown that C-reactive protein has prognostic value in
patients with renal cell cancer, but was not independent of disease
stage (Ljungberg et al, 1995; Miyata et al, 2001). These studies
included patients with stage I disease, who were unlikely to
progress, and patients with stage IV disease, who had already
progressed, and this may have confounded the assessment of the
prognostic value of an elevated circulating C-reactive protein
concentration. Indeed, Blay et al (1992) reported that, in patients
with metastatic renal cancer receiving interleukin-2 immunother-
apy, a high C-reactive protein concentration was associated with
poor survival independent of performance status.
The aim of the present study was to examine the relationship
between the systemic inflammatory response, performance status
and survival in patients undergoing alpha interferon immuno-
therapy for advanced renal cancer.
PATIENTS AND METHODS
Patients
Patients with advanced renal cell cancer at a single multi-disciplinary
clinic in the North Glasgow NHS Hospital Trust between August 1997
and October 2002 were studied. Information was abstracted from the
case notes (EB). Data for 1997–1999 were collected retrospectively
(n¼26) and that for 2000–2002 prospectively (n¼32).
Prior to immunotherapy, patients were assessed by a CT scan of
the chest, abdomen and pelvis, and where appropriate a bone scan;
performance status (ECOG-ps) was also assessed and a blood sample
was taken for measurement of C-reactive protein concentration.
Patients were treated with subcutaneous alpha-interferon at a
dosage of 10MIU three times weekly. Patients were followed up
weekly. After 12 weeks of treatment, a further CT scan was performed
and response was assessed. Patients with stable or responding disease
continued on alpha-interferon if their tolerance was acceptable.
Routine laboratory measurements of C-reactive protein con-
centration were carried out. C-reactive protein was measured by
fluorescence polarisation immunoassay using a TDX analyser and
reagents obtained from Abbott Laboratories (Abbott Park, IL,
USA). The limit of detection of the assay is a C-reactive protein
concentration of o5mgl
 1. The coefficient of variation for this
method, over the range of measurement, was less than 5%, as
established by routine quality control procedures.
Statistics
C-reactive protein concentrations were grouped either as p10/
410mgl
 1 (O’Gorman et al, 2000) or as p50/450mgl
 1 (Blay
et al, 1992) as described previously. Univariate survival analysis
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lwas performed using the Kaplan–Meier method with the logrank
test. Multivariate survival analysis and calculation of hazard ratios
(HR) were performed using Cox regression analysis. Deaths up to
31 January 2004 were included in the analysis. Analysis was
performed using SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The characteristics of patients with advanced renal cancer
receiving alpha-interferon immunotherapy (n¼58) are shown in
Table 1. The majority were male and over the age of 60 years.
Approximately 90% had an ECOG performance status of 0–1, 70
and 50% had a C-reactive protein 410 and 450mgl
 1,
respectively. Approximately half of the patients had a treatment
duration more than 12 weeks.
The minimum follow-up was 36 months and 55 (95%) patients
died during the follow-up period. On univariate survival analysis,
ECOG-ps (Po0.05), C-reactive protein (o10/410mgl
 1, Po0.05)
and treatment duration (Po0.001) were significant predictors of
survival. On multivariate analysis with ECOG-ps and C-reactive
protein entered as covariates, only C-reactive protein was a
significant independent predictor of survival (HR 2.03, 95% CI
1.09–3.80, P¼0.026). The cancer-specific survival rates at 3 years
for patients with a C-reactive protein p10/410mgl
 1 were 24 and
5%, respectively.
Of those patients with an elevated C-reactive protein concentra-
tion (410mgl
 1) 44% received alpha-interferon immunotherapy
for more than 12 weeks compared with 76% of those with a C-
reactive protein concentration in the normal range (P¼0.041,
Fisher’s exact test).
DISCUSSION
Conventionally, in patients with advanced renal cancer, the
decision whether or not to offer immunotherapy is primarily
based on performance status. However, the assessment of
performance status reflects functional status at a specific point
in time and remains subjective. For example, significant differ-
ences in the assessment of performance status have been reported
between oncologists, nurses and patients, oncologists being the
most optimistic in their assessment and patients the least (Ando
et al, 2001). There is therefore a continuing interest in prognostic
factors, which better reflect response to treatment and survival
(Bennett and Ryall, 2000; Sloan et al, 2001).
In the present study, we compared the prognostic value of
performance status and the systemic inflammatory response
(using two C-reactive protein cutoffs, p10/410mgl
 1 and p50/
450mgl
 1) in patients receiving alpha-interferon immunotherapy
for advanced renal cancer (Figure 1). In this small study, on
univariate analysis, both ECOG-ps and C-reactive protein (o10/
410mgl
 1 only) had significant prognostic value. However, when
compared in multivariate analysis, only C-reactive protein retained
independent significance and therefore it would appear that it is
superior to performance status in predicting survival following
alpha-interferon immunotherapy.
Table 1 Clinical characteristics and survival in patients with advanced
renal cancer receiving alpha interferon immunotherapy: univariate survival
analysis
Patients
58 (100%)
Survival (months)
Median (95% CI) P-value
Age (years)
p60 28 (48) 10.6 (6.3–15.0)
460 30 (52) 12.6 (5.9–19.4) 0.774
Sex
Male 41 (71) 13.5 (3.9–23.0)
Female 17 (29) 12.2 (9.0–15.4) 0.831
Performance status (ECOG)
0 11 (19) 16.2 (7.2–25.2)
1 40 (69) 13.5 (10.8–16.1) 0.046
2 7 (12) 4.3 (2.3–6.2)
C-reactive protein (mgl
 1)
p10 17 (29) 15.9 (2.4–29.5)
410 41 (71) 10.1 (4.2–16.1) 0.023
C-reactive protein (mgl
 1)
p50 33 (57) 14.1 (10.0–18.2)
450 25 (43) 5.4 (2.4–8.5) 0.073
Treatment (weeks)
p12 27 (46) 5.1 (4.4–5.8)
412 31 (54) 18.6 (14.5–22.7) o0.001
Survival (months)
Survival (months)
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Figure 1 (A) The relationship between C-reactive protein (p10mgl
 1
---, 410mgl
 1 __) and survival in patients receiving alpha-interferon
treatment for advanced renal cancer. (B) The relationship between C-
reactive protein (p50mgl
 1 ---, 450mgl
 1 __) and survival in patients
receiving alpha-interferon treatment for advanced renal cancer.
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lThese results are consistent with previous studies, which have
shown that the presence of a systemic inflammatory response (C-
reactive protein 410mgl
 1) is associated with poor outcome
independent of clinical stage and performance status (O’Gorman
et al, 2000; Scott et al, 2002; Forrest et al, 2003) and is superior to
performance status in predicting survival following chemotherapy
(Forrest et al, 2004).
The side effects of alpha-interferon immunotherapy are
significant and include a flu-like syndrome, fatigue, fever,
anorexia, myalgia, arthralgia, dry skin and mucous membranes,
mental state changes and depression. In the present study,
although approximately 90% of patients had an ECOG-ps of 0 or
1, 31 (53%) patients completed 12 weeks of therapy, with five (9%)
patients showing a complete or partial response, consistent with
the response rate (14%) in the MRC trial (MRC RCC, 1999). It was
therefore of interest that, in the present study, of those patients
with an elevated C-reactive protein concentration only 44%
received alpha-interferon immunotherapy for more than 12 weeks
compared with 76% of those with a C-reactive protein concentra-
tion in the normal range. This may explain, in part, the effect of the
systemic inflammatory response on the poor survival of patients
with advanced renal cancer receiving alpha-interferon immuno-
therapy.
The underlying basis of the relationship between the presence of
a systemic inflammatory response and poor tolerance to alpha-
interferon immunotherapy or chemotherapy (Forrest et al, 2004) is
not clear. However, it is likely to be linked to increased toxicity in
these patients. Therefore, it is of interest that the activity of the
enzyme cytochrome P450 3A, involved in biotransformation of
more than half of all drugs currently available, is compromised in
patients with an elevated C-reactive protein concentration (Rivory
et al, 2002; Slaviero et al, 2003). It may be that moderation of the
systemic inflammatory response will reduce such toxicity.
In summary, the prognosis from advanced renal cancer is very
poor with or without immunotherapy. The presence of a systemic
inflammatory response (C-reactive protein 410mgl
 1) appears to
be a useful clinical indicator of poor outcome independent of
performance status. This may assist in more appropriate selection
of patients for treatment with alpha-interferon, thus reducing the
potentially deleterious impact on an already shortened lifespan.
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